Man Group PLC Akebia Therapeutics, Inc. Transaction History

Man Group PLC

$54.1 Billion
Q3 2025

A detailed history of Man Group PLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Man Group PLC holds 124,426 shares of AKBA stock, worth $211,524. This represents 0.0% of its overall portfolio holdings.

Number of Shares

124,426

Previous 41,711 198.31%

Holding current value

$211,524

Previous $151,000 121.85%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$2.7 - $4.01 $223,330 - $331,687	82,715 Added 198.31%	124,426 $335,000
Q2 2025 Aug 14, 2025	BUY	$1.55 - $3.97 $64,652 - $165,592	41,711 New	41,711 $151,000
Q3 2022 Nov 14, 2022	BUY	$0.3 - $0.46 $4,011 - $6,150	13,371 Added 43.84%	43,873 $14,000
Q2 2022 Aug 15, 2022	BUY	$0.32 - $0.67 $9,760 - $20,436	30,502 New	30,502 $11,000
Q2 2021 Aug 16, 2021	SELL	$2.83 - $4.2 $67,237 - $99,787	-23,759 Closed	0 $0

Q1 2021 May 17, 2021	SELL	$2.92 - $5.06 $347,617 - $602,377	-119,047 Reduced 83.36%	23,759 $80,000
Q4 2020 Feb 16, 2021	SELL	$2.22 - $3.78 $10,505 - $17,886	-4,732 Reduced 3.21%	142,806 $400,000
Q3 2020 Nov 16, 2020	SELL	$2.39 - $13.08 $48,457 - $265,197	-20,275 Reduced 12.08%	147,538 $370,000
Q2 2020 Aug 14, 2020	SELL	$6.67 - $13.58 $342,124 - $696,558	-51,293 Reduced 23.41%	167,813 $2.28 Million
Q1 2020 May 15, 2020	SELL	$4.1 - $10.24 $496,382 - $1.24 Million	-121,069 Reduced 35.59%	219,106 $1.66 Million
Q4 2019 Feb 18, 2020	SELL	$3.16 - $6.73 $79,543 - $169,407	-25,172 Reduced 6.89%	340,175 $2.15 Million
Q3 2019 Nov 14, 2019	SELL	$3.55 - $5.4 $2.02 Million - $3.07 Million	-569,303 Reduced 60.91%	365,347 $1.43 Million
Q2 2019 Aug 14, 2019	BUY	$4.1 - $8.05 $1.42 Million - $2.79 Million	346,242 Added 58.84%	934,650 $4.52 Million
Q1 2019 May 15, 2019	BUY	$5.41 - $8.73 $1.03 Million - $1.66 Million	190,604 Added 47.91%	588,408 $4.82 Million
Q4 2018 Feb 14, 2019	BUY	$5.39 - $9.15 $494,182 - $838,917	91,685 Added 29.95%	397,804 $2.2 Million
Q3 2018 Nov 14, 2018	BUY	$7.44 - $10.65 $609,336 - $872,235	81,900 Added 36.53%	306,119 $2.7 Million
Q2 2018 Aug 14, 2018	BUY	$9.15 - $11.34 $208,620 - $258,552	22,800 Added 11.32%	224,219 $2.24 Million
Q1 2018 May 15, 2018	BUY	$9.53 - $15.68 $1.92 Million - $3.16 Million	201,419 New	201,419 $1.92 Million

Others Institutions Holding AKBA

# of Institutions

189

Shares Held

121M

Call Options Held

267K

Put Options Held

280K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $313M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account